Featured Publications
Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination
Asashima H, Kim D, Wang K, Lele N, Buitrago-Pocasangre N, Lutz R, Cruz I, Raddassi K, Ruff W, Racke M, Wilson J, Givens T, Grifoni A, Weiskopf D, Sette A, Kleinstein S, Montgomery R, Shaw A, Li F, Fan R, Hafler D, Tomayko M, Longbrake E. Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination. JCI Insight 2023, 8: e168102. PMID: 37606046, PMCID: PMC10543713, DOI: 10.1172/jci.insight.168102.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 mRNA vaccinationB-cell-depleted patientsB-cell depletionAntibody responseMRNA vaccinationThird doseCell depletionT cellsClaude D. Pepper Older Americans Independence CenterB cellsNational Multiple Sclerosis SocietyAnti-CD20 antibodySpike-specific antibodiesMultiple Sclerosis SocietyLow cumulative exposureLogistic regression modelsImportant clinical needCD20 therapyCD20 treatmentMost patientsThird vaccineSerologic responseVaccine dosesMRNA vaccinesVaccination strategies
2023
Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection
Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection. Small Methods 2023, 7: e2300594. PMID: 37312418, PMCID: PMC10592458, DOI: 10.1002/smtd.202300594.Peer-Reviewed Original ResearchConceptsB cell depletion therapyAcute COVID infectionAnti-spike IgGHigh-risk patientsCoronavirus disease-19COVID-19 pathologyDepletion therapyVaccine protectionAntibody responseCOVID infectionHematologic malignanciesImmune protectionDisease-19Healthy donorsMultiple time pointsSerology assaysBlood samplesSoluble markersB cellsImmunization strategiesPatientsFunctional deficiencySerological analysisTime pointsClonotype diversity
2022
Impact of resilience, social support, and personality traits in patients with neuroinflammatory diseases during the COVID-19 pandemic
Jakimovski D, Kavak KS, Longbrake EE, Levit E, Perrone CM, Bar-Or A, Benedict RH, Riley CS, De Jager PL, Venkatesh S, Walker ELS, Xia Z, Weinstock-Guttman B, Collaborative M. Impact of resilience, social support, and personality traits in patients with neuroinflammatory diseases during the COVID-19 pandemic. Multiple Sclerosis And Related Disorders 2022, 68: 104235. PMID: 36283322, PMCID: PMC9548342, DOI: 10.1016/j.msard.2022.104235.Peer-Reviewed Original ResearchWorsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic
Levit E, Cohen I, Dahl M, Edwards K, Weinstock-Guttman B, Ishikawa T, Kavak K, Leavitt V, Nelson K, Onomichi K, Bar-Or A, Perrone C, Riley C, Venkatesh S, De Jager PL, Xia Z, Longbrake EE, Collaborative M. Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic. Multiple Sclerosis And Related Disorders 2022, 58: 103482. PMID: 35016114, PMCID: PMC8742609, DOI: 10.1016/j.msard.2021.103482.Peer-Reviewed Original ResearchConceptsPhysical functionDepression scoresCOVID-19 pandemicPhysical disabilityNeurological inflammatory diseasesMajor academic medical centerAcademic medical centerHigher baseline levelsLack of diseaseDisease durationStudy entryTherapy useNeuroinflammatory diseasesMale genderInflammatory diseasesPhysical functioningMedical CenterMood symptomsDepressive symptomsSmall cohortBaseline levelsSerial surveysSignificant depressionOlder ageWorse depression
2021
Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data
Epstein S, Xia Z, Lee AJ, Dahl M, Edwards K, Levit E, Longbrake EE, Perrone C, Kavak K, Weinstock-Guttman B, Diallo F, Ricci A, Riley CS, De Jager PL, Farber R, Wesley SF, Collaborative M. Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data. Multiple Sclerosis And Related Disorders 2021, 57: 103433. PMID: 34923427, PMCID: PMC8638239, DOI: 10.1016/j.msard.2021.103433.Peer-Reviewed Original ResearchConceptsNeuromyelitis optica spectrum disorderSelf-reported side effectsNeuroinflammatory diseasesSARS-CoV-2Multiple sclerosisSide effectsSARS-CoV-2 vaccine trialsCross-sectional observational studySafety/tolerability dataAsymptomatic control populationNeurologist-confirmed diagnosisRadiologic disease activityRecurrent neurologic symptomsSignificant vaccine hesitancyOptica spectrum disorderAntibody-mediated diseasesVaccine side effectsViral vector vaccinesReal-world evidenceMultiple academic centersNID patientsUnvaccinated patientsVaccines surveyDisease activityNeurologic eventsA New England COVID-19 Registry of Patients With CNS Demyelinating Disease
Money KM, Mahatoo A, Samaan S, Anand P, Baber U, Bailey M, Bakshi R, Bouley A, Bower A, Cahill J, Houtchens M, Katz J, Lathi E, Levit E, Longbrake EE, McAdams M, Napoli S, Raibagkar P, Wade P, Sloane JA. A New England COVID-19 Registry of Patients With CNS Demyelinating Disease. Neurology Neuroimmunology & Neuroinflammation 2021, 8: e1046. PMID: 34341094, PMCID: PMC8362350, DOI: 10.1212/nxi.0000000000001046.Peer-Reviewed Original ResearchConceptsCOVID-19 infectionHospitalization ratesRisk factorsSevere coronavirus disease 2019 (COVID-19) infectionDisease-modifying therapy useCoronavirus disease 2019 (COVID-19) infectionStepwise multivariate logistic regressionCNS Demyelinating DiseaseNausea/vomitingAbsolute lymphocyte countIndependent risk factorNumber of comorbiditiesDisease 2019 infectionPatient risk factorsRisk of hospitalizationCOVID-19 cohortDisease-modifying therapiesCase fatality rateMultivariate logistic regressionCOVID-19 registryFisher's exact testDemyelinating diseaseClinical characteristicsLymphocyte countNeurologic symptomsMOG-associated encephalitis following SARS-COV-2 infection
Peters J, Alhasan S, Vogels CBF, Grubaugh ND, Farhadian S, Longbrake EE. MOG-associated encephalitis following SARS-COV-2 infection. Multiple Sclerosis And Related Disorders 2021, 50: 102857. PMID: 33647592, PMCID: PMC7900751, DOI: 10.1016/j.msard.2021.102857.Peer-Reviewed Case Reports and Technical NotesManifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases
Levin SN, Venkatesh S, Nelson KE, Li Y, Aguerre I, Zhu W, Masown K, Rimmer KT, Diaconu CI, Onomichi KB, Leavitt VM, Levine LL, Strauss‐Farber R, Vargas WS, Banwell B, Bar‐Or A, Berger JR, Goodman AD, Longbrake EE, Oh J, Weinstock‐Guttman B, Thakur KT, Edwards KR, Riley CS, Xia Z, De Jager PL, Collaborative M. Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases. Annals Of Clinical And Translational Neurology 2021, 8: 918-928. PMID: 33616290, PMCID: PMC8013889, DOI: 10.1002/acn3.51314.Peer-Reviewed Original ResearchConceptsNeuroinflammatory disordersMultiple sclerosisCOVID-19Year-long prospective studyPotential risk factorsPatient reported experienceTesting shortagesNeurological disabilityLiver diseaseNeuroinflammatory diseasesTelemedicine visitsProspective studyPotential confoundersMS casesRisk factorsNeurological careSevere casesTreatment changesSymptom criteriaEarly changesMore depressionReference groupCase prevalenceDisease managementGreater likelihood